Company intelligence / Profile preview

BioHealthonomics

Reno, Nevada, United States

Ownership: Private
Development stage: Other

Overview

BioHealthonomics is a clinical-stage biotechnology company dedicated to developing innovative therapies for neurological and inflammatory diseases, with a primary focus on migraine. The company's lead program, BH-017, is a proprietary formulation designed to provide rapid relief for acute migraine sufferers by optimizing the delivery of established therapeutic agents. By leveraging known compounds and enhancing their pharmacokinetic profiles, BioHealthonomics aims to reduce clinical development risks while addressing significant unmet medical needs in the central nervous system space. The company is headquartered in the United States and focuses on advancing its pipeline through strategic clinical trials.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on BioHealthonomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioHealthonomics.

Explore the full profile